Download PDF
psychoneuro 2003; 29(5): 240-244
DOI: 10.1055/s-2003-39633
Übersicht

© Georg Thieme Verlag Stuttgart · New York

Venlafaxin ist kein SSRI, sondern ein SNRI, und das ist relevant

Jürgen Fritze1 2 , Barbara Schneider2 , Bernhard Weber2
  • 1Verband der privaten Krankenversicherung, Köln
  • 2Zentrum der Psychiatrie, Universität Frankfurt am Main
Further Information

Publication History

Publication Date:
30 May 2003 (online)

   Permissions and Reprints

Zusammenfassung

Venlafaxin ist ein selektives Antidepressivum, indem es - wie selektiv-serotonerge Antidepressiva (SSRI) - frei von den anticholinergen, antihistaminergen, antiadrenergen und kardiotoxischen Nebenwirkungen der trizyklischen Antidepressiva ist. Venlafaxin hemmt aber - anders als die SSRI - nicht nur die synaptische Wiederaufnahme von Serotonin, sondern insbesondere in höherer Dosis auch die von Noradrenalin (sog. duales Wirkprinzip der selektiven Serotonin-Noradrenalin-Reuptake-Inhibition, SNRI). Gemäß mehrerer Meta-Analysen ist die Rate von Vollremissionen bei Depression unter Venlafaxin signifikant höher als unter SSRI. Dieser Überlegenheit liegt wahrscheinlich der duale Mechanismus zu Grunde. Venlafaxin ist als einziges Antidepressivum auch für die Indikation der Rückfall- und Rezidivprophylaxe formal zugelassen. Ob das duale Wirkprinzip auch hier Vorteile bietet, müsste durch Vergleichsstudien geprüft werden. Venlafaxin ist neben Paroxetin das einzige zur Behandlung der generalisierten Angststörung formal zugelassene Antidepressivum. Ob das duale Wirkprinzip in dieser Indikation Vorteile bietet, müsste auch hier durch Vergleichsstudien geprüft werden.

Summary

Venlafaxine is a selective antidepressant in that - like the selective serotonin reuptake inhibitors (SSRI) - it is free from the anticholinergic, antihistaminergic, antiadrenergic and cardiotoxic side-effects of tricyclic antidepressants. Venlafaxine, however, differs from the SSRIs by inhibiting not only the synaptic reuptake of serotonin but - especially at higher dosages - also that of norepinephrine (the so-called dual mechanism of selective serotonin-norepinephrine-reuptake-inhibition, SNRI). According to several meta-analyses the rate of full remissions of depression is significantly higher under venlafaxine than under SSRIs. This superiority is probably due to the dual mechanism of action. Venlafaxine is the only antidepressant formally approved for relapse and recurrence prevention. Further studies comparing venlafaxine to SSRIs are needed to test whether the dual mechanism is advantageous also in this indication. Venlafaxine is beside paroxetine the only antidepressant formally approved for generalized anxiety disorder. Again, further studies comparing venlafaxine to SSRIs are needed to test whether the dual mechanism is advantageous.

Key Words:

Venlafaxine - depression - efficacy - dual mechanism of action - response rate

Literatur

  • 1 Allgulander C, Hackett D, Salinas E. Venlafaxin extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study.  Br J Psychiatry. 2001;  179 15-22
    CrossrefPubMedGoogle Scholar
  • 2 Anderson IM. Meta-analytical studies on new antidepressants.  Br Med Bull. 2001;  57 161-178
    CrossrefPubMedGoogle Scholar
  • 3 Baron BM, Ogden A-M, Siegel BW. Rapid down regulation of ß-adrenoceptors by co-administration of desipramine and fluoxetine.  Eur J Pharmacol. 1988;  154 125-134
    CrossrefPubMedGoogle Scholar
  • 4 Bauer M, Whybrow P, Angst J, Versiani M, Möller HJ. WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. . World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder.  World J Biol Psychiatry. 2002;  3 5-43
    CrossrefPubMedGoogle Scholar
  • 5 Benkert O, Gründer G, Wenzel H, Hackett D. A randomized double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia.  J Psychiatr Res. 1996;  30 441-451
    CrossrefPubMedGoogle Scholar
  • 6 Doyle JJ, Casciano J, Arikian S, Tarride E J, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute Major Depressive Disorder (MDD): A comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.  Value in Health. 2001;  4 16-31
    CrossrefPubMedGoogle Scholar
  • 7 Einarson TR, Arikian SR, Casciano J, Doyle JJ. Comparison of extended release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.  Clin Ther. 1999;  21 296-308
    CrossrefPubMedGoogle Scholar
  • 8 Entsuah AR, Rudolph RL, Hackett D, Miska S. Efficacy of venlafaxine and placebo during long-term treatment of depression: A pooled analysis of relapse rates.  Int Clin Psychopharmacology. 1996;  11 137-145
    PubMedGoogle Scholar
  • 9 Entsuah R, Huang H, Willard L. Venlafaxine and SSRIs: pooled remission analysis (Mega-analysis of 31 studies of > 7000 patients).  Poster bei: World Congress of Psychiatry (WCP), Yokohama, Japan. 2002; 
    PubMedGoogle Scholar
  • 10 Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.  J Affect Disord. 1998;  47 55-62
    CrossrefPubMedGoogle Scholar
  • 11 Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom.  PharmacoEconomics. 2000;  18 143-148
    PubMedGoogle Scholar
  • 12 Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs: Meta-regression analysis.  Br J Psychiatry. 2000;  177 292-302
    CrossrefPubMedGoogle Scholar
  • 13 Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.  JAMA. 2000;  283 3082-3088
    CrossrefPubMedGoogle Scholar
  • 14 Gorman JM. Treatment of generalized anxiety disorder.  J Clin Psychiatry. 2002;  63 17-23
    PubMedGoogle Scholar
  • 15 Guelfi JD, White C, Hackett D, Guichoux JY, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia.  J Clin Psychiatry. 1995;  56 450-458
    PubMedGoogle Scholar
  • 16 Horst WD, Preskorn SH. Rev Contemporary Pharmacotherapy.  1998;  9 293-302
    PubMedGoogle Scholar
  • 17 Katz IR, Reynolds 3rd CF, Alexopoulos GS, Hackett D. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials.  J Am Geriatr Soc. 2002;  50 18-25
    CrossrefPubMedGoogle Scholar
  • 18 Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.  J Clin Psychiatry. 2001;  62 888-893
    PubMedGoogle Scholar
  • 19 Montgomery SA, Sheehan DV, Meoni P, Haudiquet V, Hackett D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR.  J Psychiatr Res. 2002;  36 209-217
    CrossrefPubMedGoogle Scholar
  • 20 Moyer JA, Andree TH, Haskins JT. The preclinical pharmacological profile of venlafaxine: A novel antidepressant agent.  (Abstr) Clin Neuropharmacol. 1992;  15
    PubMedGoogle Scholar
  • 21 Moyer JA, Muth EA, Haskins JT. In vivo antidepressant profiles of the novel bicyclic compounds Wy-45,030 and Wy-45,881.  (Abstr) Soc Neurosci. 1984;  10 261
    PubMedGoogle Scholar
  • 22 Muth EA, Haskins JT, Moyer JA, Husbands G, Nielson ST, Sigg E. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.  Biochem Pharmacol. 1986;  35 4493-4497
    CrossrefPubMedGoogle Scholar
  • 23 Nemeroff CB, Entsuah AR, Kunz N. Remission rates during long-term treatment of depression with venlafaxine.  Abstractband der American Psychiatric Association, Philadelphia. 2002;  18-23
    PubMedGoogle Scholar
  • 24 Redrobe JP, Bourin M, Colombel MC, Baker GB. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity.  Psychopharmacology. 1998;  138 1-8
    CrossrefPubMedGoogle Scholar
  • 25 Rickels K, Derivan A, Entsuah S R Miska, Rudolph R. Rapid onset of antidepressant activity with venlafaxine treatment.  Depression. 1995;  3 146-153
    PubMedGoogle Scholar
  • 26 Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.  Am J Psychiatry. 2000;  157 968-974
    CrossrefPubMedGoogle Scholar
  • 27 Rudolph RL, Entsuah AR, Aguiar L, Derivan A. Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study.  Abstract presented at the 11th annual meeting of the European College of Neuropschopharmacology 1998 Oct 31-Nov 4, Paris/France.
    PubMedGoogle Scholar
  • 28 Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.  Journal of Affective Disorders. 1999;  56 171-181
    CrossrefPubMedGoogle Scholar
  • 29 Salinas for the Venlafaxine Study Group . Once-daily extended release (XR) venlafaxine versus paroxetine in outpatients with major depression Abstract, Biolog.  Psychiatry. 1997;  42 1S-297S
    PubMedGoogle Scholar
  • 30 Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.  Cell Mol Neurobiol. 1999;  19 467-89
    CrossrefPubMedGoogle Scholar
  • 31 Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.  British Journal of Psychiatry. 2002;  180 396-494
    CrossrefPubMedGoogle Scholar
  • 32 Thase M, Entsuah A, Rudolph R. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.  British Journal of Psychiatry. 2001;  178 234-241
    CrossrefPubMedGoogle Scholar
  • 33 Wellington K, Perry CM. Venlafaxine extended-release: A review of its use in the management of major depression.  CNS Drugs. 2001;  15 643-669
    PubMedGoogle Scholar

Korrespondenzadresse:

Prof. Dr. med. Jürgen Fritze

Asternweg 65

50259 Pulheim